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Summary
Themitogen-activated protein kinases (MAPK) play critical roles in the pathogenesis of diabetes and obesity. TheMAPKs are
inactivated by MAPK phosphatases (MKPs) either in the cytosol or nucleus. Here we show that mice lacking the nuclear-
localized MKP, MKP-1 (mkp-12/2), have enhanced Erk, p38 MAPK and c-Jun NH2-terminal kinase (JNK) activities in
insulin-responsive tissues as compared with wild-type mice. Although JNK promotes insulin resistance, mkp-12/2 mice
exhibited unimpaired insulin-mediated signaling and glucose homeostasis. We reconciled these results by demonstrating
that in mkp-12/2 mice, JNK activity was increased in the nucleus, but not the cytosol. Significantly, mkp-12/2 mice are
resistant to diet-induced obesity due to enhanced energy expenditure, but succumb to glucose intolerance on a high fat
diet. These results suggest that nuclear regulation of the MAPKs by MKP-1 is essential for the management of metabolic
homeostasis in a manner that is spatially uncoupled from the cytosolic actions of the MAPKs.Introduction
Stress-responsive stimuli activate a family of enzymes known as
the mitogen-activated protein kinases (MAPKs) (Davis, 2000;
Ono and Han, 2000). p38 MAPK and c-Jun NH2-terminal kinase
(JNK) are stress-responsive MAPKs that initiate adaptive events
such as gene expression, differentiation, metabolism and
apoptosis (Davis, 2000; Ono and Han, 2000). A wealth of infor-
mation exists about the activators of the MAPKs, the MAPK
kinases, and their physiological roles (Brancho et al., 2003;
Nishina et al., 1999; Tournier et al., 1999). In contrast, little is
known about the in vivo role of the MAPK phosphatases
(MKPs) that inactivate the MAPKs by dephosphorylation of the
regulatory threonine and tyrosine residues on MAPK (Camps
et al., 2000; Keyse, 2000).
Metabolic syndrome is a clinical constellation of symptoms
that include obesity, hypertension, insulin resistance, glucose
intolerance, nonalcoholic fatty liver disease, and hyperlipidemia
(Kopelman, 2000). In many cases, metabolic syndrome is asso-
ciated with increased inflammatory responses. Elevated pro-
duction of cytokines (e.g., TNF-a) and free fatty acids are impli-
cated in the etiology of obesity-induced insulin resistance (Bays
et al., 2004) which often results in the activation of the MAPKs.
Additionally, the MAPKs have been reported to become acti-
vated following metabolic stresses such as high-fat feeding,
atherogenesis and genetic models of obesity. For instance,
JNK activity has been shown to be elevated following a high-
fat diet (HFD) and in genetic models of obesity in the liver, skel-
etal muscle and adipose tissue (Hirosumi et al., 2002). p38CELL METABOLISM 4, 61–73, JULY 2006 ª2006 ELSEVIER INC. DOIMAPK is hyperactivated in models of diet-induced obesity in
skeletal muscle (Leng et al., 2004), liver and heart (Li et al.,
2005). Whereas, in genetic models of obesity, Erk activity is el-
evated in the liver (Gum et al., 2003) and adipose tissue (Bost
et al., 2005). The pathophysiological consequence of altered
MAPK activity in metabolic syndrome still remains to be fully de-
fined. However, JNK has been proposed to negatively regulate
insulin signaling thereby promoting insulin resistance (Hirosumi
et al., 2002), whereas p38 MAPK is implicated in the positive
regulation of energy expenditure (Puigserver et al., 2001). Within
a physiological context, Erk, p38 MAPK, and JNK act simulta-
neously and often times in combination to exert a biological
response. Thus, the actions of the MAPKs must be tightly
integrated in order to maintain normal physiology. The conse-
quences of the combined actions of altered MAPK signaling
that likely occurs in diseases, such as metabolic syndrome,
are unknown.
There are 11 members of the classical MKP family all of which
inactivate the MAPKs by dephosphorylation. The MKPs have
overlapping and distinct sub-cellular localization, expression
pattern, and substrate specificity toward theMAPK family mem-
bers (Camps et al., 2000; Keyse, 2000). MKP-1 is the archetypal
member of the cdc25 homology domain-containing MKP family
of dual-specificity phosphatases (Camps et al., 2000; Keyse,
2000). MKP-1 was identified as a stress-responsive immedi-
ate-early gene following oxidative stress (Keyse and Emslie,
1992) and in response to liver regeneration (Mohn et al., 1991).
MKP-1 localizes to the nucleus through a LXXLL motif in its
amino terminus (Wu et al., 2005), and it contains a carboxyl10.1016/j.cmet.2006.05.010 61
A R T I C L EFigure 1. mkp-12/2 mice are lean due to reduced
body adiposity
A) Analysis of body weight of male mkp-1+/+ (n =
7–10) and mkp-12/2 (n = 9–11) littermates on
a chow diet.
B) Whole-body adiposity and lean mass of 13- to
16-week-old male mkp-1+/+ (n = 17) and mkp-12/2
(n = 15) mice.
C) Representative image of abdominal adiposity in
10-month-old mkp-1+/+ and mkp-12/2 littermates.
D) Food consumption in mkp-1+/+ (n = 6) and
mkp-12/2 (n = 7) mice.
E) Activity of mkp-1+/+ (n = 6) and mkp-12/2 (n = 7)
mice. Data shown are mean 6 SEM (*; p < 0.05, **;
p < 0.01).terminus phosphatase domain. Several groups have shown that
cells derived from MKP-1-deficient mice exhibit enhanced p38
MAPK, JNK and Erk activities in response to various stimuli
(Nimah et al., 2005; Wu and Bennett, 2005; Zhao et al., 2004).
In addition, mice lacking MKP-1 are sensitive to LPS-induced
endotoxemia suggesting that MKP-1 plays an important role in
the innate immune response (Chi et al., 2006; Hammer et al.,
2006; Salojin et al., 2006; Zhao et al., 2006). MKP-1 has been
suggested to be involved in obesity and diabetes. In mice,
MKP-1 is overexpressed following a HFD (Reddy et al., 2004)
as well as in a rat model of diabetes (Chin et al., 1995), whether
MKP-1 plays a physiological role in regulating metabolic ho-
meostasis remains to be determined.
Herewe show thatmice lackingMKP-1 have enhancedMAPK
activity in insulin-responsive tissues. MKP-1-deficient mice are
lean and exhibit increased levels of energy expenditure in the
context of unimpaired insulin action. These data define MKP-1
as a physiological regulator of metabolic homeostasis and addi-
tionally reveal some unexpected complexities as to how spatial
integration of the MAPK pathways influence metabolism.
Results
mkp-12/2 mice are lean due to reduced body adiposity
Wild-type (mkp-1+/+), heterozygotic (mkp-1+/2) and homozy-
gotic (mkp-12/2) mice for MKP-1 were born at the expected
Mendelian frequency as reported previously (Dorfman et al.,
1996). Genotyping of mkp-1+/+, mkp-1+/2 and mkp-12/2 mice62confirmed the presence of the neomycin cassette insertion
within exon 2 of either one or both alleles of mkp-1+/2 and
mkp-12/2 mice, respectively (Wu and Bennett, 2005). Although
no significant differences in pre-weaning weights were ob-
served between mkp-1+/+ and mkp-12/2 mice (Figure S1 in
the Supplemental Data available with this article online), when
malemkp-12/2micewere weaned on to a chowdiet they gained
weight at a slower rate thanmkp-1+/+ littermates (Figure 1A), and
by 20 weeks of age, mkp-12/2 mice gained significantly (p <
0.01) less weight thanmkp-1+/+ littermates (Figure 1A). This dis-
parity in body mass became exacerbated as these mice aged,
such that by 24 weeks of age, mkp-12/2 mice weighed 14%
(p < 0.001) less than mkp-1+/+ littermates (Figure 1A). Female
mkp-12/2 mice were also resistant to weight gain on a chow
diet, albeit to a lesser extent than males (Figure S2). To investi-
gate the etiology of the reduced body mass in mkp-12/2 mice
we performed spectroscopic imaging to measure whole body
fat and lean mass. mkp-12/2 mice exhibited 21% less fat
mass (p < 0.05), but lacked significant (p > 0.1) differences in
lean mass, as compared with mkp-1+/+ mice (Figure 1B). By
10 months of age,mkp-12/2mice were visibly leaner, and accu-
mulated dramatically reduced amounts of abdominal adiposity
(Figure 1C). Despite the observation that mkp-12/2 mice were
lean they consumed an equivalent amount of food as mkp-1+/+
controls (Figure 1D), and exhibited comparable levels of loco-
motor activity (Figure 1E). These results indicate that the
reduced adiposity observed in mkp-12/2 mice was unlikely to
be due either to diminished food consumption or increasedCELL METABOLISM : JULY 2006
MKP-1 regulates metabolism and body masslocomotor activity. Thus, mice lacking MKP-1 expression
appear to be resistant to weight gain due to reduced body
adiposity.
Consistent with the marked reduction in total body adiposity,
epididymal fat pads isolated from mkp-12/2 mice were signifi-
cantly smaller by 37% (p < 0.05) as compared with mkp-1+/+
mice (Figure 2A). We performed morphometric analyses on
white adipose tissue (WAT) sections to determine the cross-
sectional area of adipocytes. Consistent with the decrease in
epididymal fat pad mass (Figure 2A), there was a 39% (p <
0.05) decrease in the mean cross-sectional area of adipocytes
isolated from mkp-12/2 mice as compared with mkp-1+/+ mice
(Figures 2B and 2C). These observations imply that mkp-12/2
mice have reduced fat pad mass as a consequence of dimin-
ished adipocyte lipid content. To link MKP-1 to this altered
body composition we measured the activities of the MAPKs in
the epididymal fat pads of mkp-1+/+ and mkp-12/2 mice. We
found that p38 MAPK, JNK and Erk were all hyper-activated
by w2-fold in WAT from mkp-12/2 mice as compared with
mkp-1+/+mice (Figure 2D, left panel) and that MAPK expression
levels were not altered inmkp-12/2mice (Figure 2D, right panel).
These results demonstrate that MKP-1 plays a major role in the
dephosphorylation of the MAPKs in WAT and suggest that
MKP-1 is important for the regulation of adipocyte lipid
metabolism.
To investigate the nature of the reduced fat pad mass we
asked whether MKP-1 was involved in promoting adipogenesis.
Primary mouse embryo fibroblasts (MEFs) derived from
mkp-1+/+ and mkp-12/2 mice were induced to undergo adipo-
genesis. The extent of adipogenesis in mkp-1+/+ and
mkp-12/2 MEFs was visualized by staining with Oil red O for
the accumulation of lipid. As shown in Figure 2E, both
mkp-1+/+ and mkp-12/2 MEFs were equally efficient at under-
going adipogenic conversion as measured by assessing lipid
content. Thus, in this setting MKP-1 does not appear to be
critical for adipocyte differentiation.
Regulation of hepatic lipid metabolism and PPARa
activity by MKP-1
The livers of young mkp-12/2 mice were not markedly different
in size tomkp-1+/+ mice (Figure 3A). However, in aged mice, we
found that the livers of mkp-12/2 mice did not increase in mass
and were up to 25% (p < 0.001) smaller thanmkp-1+/+mice (Fig-
ure 3A). In addition,mkp-12/2mice contained 36% less hepatic
triglycerides (p = 0.06) thanmkp-1+/+ mice (Figure 3B). Livers of
aged mkp-12/2 mice (w10 months) were markedly reduced in
the amount of lipid content as compared with mkp-1+/+ litter-
mates (Figure 3C), suggesting that mkp-12/2mice are resistant
to the acquisition of a fatty liver on a chow diet. The activities of
the MAPKs in the livers of mkp-1+/+ and mkp-12/2 mice were
measured. p38 MAPK and JNK were found to be hyper-
activated byw2-3 fold in the livers ofmkp-12/2mice (Figure 3D,
left panel). Erk activity was slightly, but consistently, reduced in
mkp-12/2 mice as compared with mkp-1+/+ littermates
(Figure 3D, left panel). No differences in the expression of these
MAPKswere observed in the livers ofmkp-12/2mice (Figure 3D,
right panel). The observation thatmkp-12/2mice were resistant
to the accumulation of hepatic triglycerides, suggested that
these mice could have increased levels of hepatic fatty acid
oxidation. Consistent with this, upon fasting mkp-12/2 mice
had increased expression levels (w2-fold) of the liver isoformCELL METABOLISM : JULY 2006of carnitine palmitoyltransferase I (Figure 3E), a key rate-limiting
enzyme in the hepatic fatty acid b-oxidation pathway. Thus, in
the liver, MKP-1 functions as a major MKP for the inactivation
Figure 2. Enhanced white adipose tissue MAPK activity and reduced adipocyte
size in mkp-12/2 mice
A) Weight of epididymal fat pads from 13- to 16-week-old male mkp-1+/+ (n = 8)
and mkp-12/2 (n = 6) mice maintained on a chow diet.
B) Cross-sectional area of adipocytes from mkp-1+/+ (n = 6) and mkp-12/2 (n = 5)
mice. Data shown (A and B) are mean 6 SEM (*; p < 0.05).
C) Representative histological sections of epididymal fat pads.
D) Left panel: p38 MAPK, JNK and Erk2 activity assays in WAT frommkp-1+/+ and
mkp-12/2 mice. The mean 6 SEM (n = 4–10) fold-change of MAPK activity as
determined by densitometric analyses is shown below each representative auto-
radiograph. Right panel: total p38 MAPK, JNK1, and Erk1/2 levels in fat pads of
mkp-1+/+ and mkp-12/2 mice.
E)Differentiation of primarymkp-1+/+ andmkp-12/2MEFs showing representative
photomicrographs of Oil Red O-stained MEFs and below quantitative assessment
of Oil Red O staining from three separate experiments (mean 6 SEM).63
A R T I C L EFigure 3. Regulation of hepatic lipid metabolism
and PPARa activation by MKP-1
A) Liver weights were determined from 11- to
16-week-old male mkp-1+/+ (n = 4) and mkp-12/2
(n = 5) mice (young) and 28- to 40-week-old male
mkp-1+/+ (n = 9) and mkp-12/2 (n = 13) mice (old).
B) Hepatic triglyceride levels were determined from
livers isolated from 13- to 17-week-old mkp-1+/+
(n = 7) and mkp-12/2 (n = 5) male mice.
C) Representative histological analysis of liver
sections from 6-month-old male mkp-1+/+ and
mkp-12/2 littermates (upper panel) and Oil-red-O
(lower panel) staining. Graph (right) shows quanti-
tation of Oil-red-O staining as a fold difference
between male mkp-1+/+ (n = 4) relative to littermate
mkp-12/2 mice (n = 4). Data shown (A–C) are
mean 6 SEM (#; p < 0.001).
D) Left panel: p38 MAPK, JNK and Erk2 activity
assays in livers from mkp-1+/+ and mkp-12/2 mice.
The mean 6 SEM (n = 4–10) fold-change of MAPK
activity as determined by densitometric analyses is
shown below each representative autoradiograph.
Right panel: total p38 MAPK, JNK1 and Erk1/2 levels
in livers of mkp-1+/+ and mkp-12/2 mice.
E) Representative immunoblot of CPT-IL expression
in the liver of fasted mkp-1+/+ and mkp-12/2 mice.
Below is the corresponding densitometric analysis
of the relative expression levels of CPT-1L normal-
ized to actin (mean 6 SEM) from mkp-1+/+ (n = 5)
and mkp-12/2 (n = 6) mice.
F) Primary hepatocytes isolated from mkp-1+/+ and
mkp-12/2 mice were transfected with (ACO)3-TK-
Luc and Renilla. Hepatocytes were either left
untreated (2) or were treated with ciprofibrate
(200 mM) or ciprofibrate (200 mM) plus SB203580
(5 mM). Data represents the mean fold-change 6
SEM from four separate experiments.of p38 MAPK and JNK and it also regulates hepatic lipid me-
tabolism.
In the liver, the peroxisome proliferator-activated receptor-a
(PPARa) (Vega et al., 2000) plays an important role in regulating
the expression of genes involved in hepatic triglyceride metab-
olism. It has been suggested that PPARa activity can be regu-
lated in the nucleus by p38MAPKwhich phosphorylates PPARa64to increase its sensitivity to ligand-mediated activation and
co-activation by the PPARg co-activator-1 (PGC-1) (Barger
et al., 2001). Because MKP-1 appears to negatively regulate
p38 MAPK in the liver (Figure 3D), we hypothesized that it could
function to attenuate p38 MAPK, and subsequently, PPARa ac-
tivity and sensitivity to ligand-mediated activation. To test this,
a PPARa response element identified in the rat acyl CoA oxidaseCELL METABOLISM : JULY 2006
MKP-1 regulates metabolism and body massFigure 4. Enhanced MAPK activity and mitochondrial oxygen consumption in skeletal muscle of mkp-12/2 mice
A) Left panel: p38 MAPK, JNK and Erk2 activity assays in skeletal muscle frommkp-1+/+ andmkp-12/2mice. The mean6 SEM (n = 4–10) fold-change of MAPK activity as
determined by densitometric analyses is shown below each representative autoradiograph. Right panel: total p38 MAPK, JNK1, and Erk1/2 levels in skeletal muscle of
mkp-1+/+ and mkp-12/2 mice.
B) Basal oxygen consumption rate (Vo) and maximal oxygen consumption rates (Vmax) were measured from high oxidative (red) or low oxidative (white) portions of the
vastus lateralis (VL) muscle isolated from 12- to 14-week-old mkp-1+/+ (n = 3) and mkp-12/2 littermates (n = 3).
C) Real-time quantitative PCR represented as arbitrary levels of mitochondrial DNA normalized to skeletal muscle nuclear DNA in red and white VL muscle frommkp-1+/+
(n = 5) and mkp-12/2 mice (n = 5).
D) Tissue homogenates prepared from the gastrocnemius of fasted mkp-1+/+ and mkp-12/2 (11-14 weeks) male mice were subjected to immunoblot analyses with
anti-UCP-3 antibody. Results shown are the mean 6 SEM of fold-change in UCP-3 expression normalized to Erk2 from mkp-1+/+ (n = 5) and mkp-12/2 (n = 4) mice.(ACO) promoter fused to luciferase, (ACO)3-TK-luc (Barger et al.,
2000; Barger et al., 2001), was transfected into hepatocytes
derived frommkp-1+/+ andmkp-12/2mice. Basal PPARa activ-
ity was found to be consistently higher byw30% in hepatocytes
derived from mkp-12/2 mice (Figure 3F). We then determined
whether PPARa activity in hepatocytes of mkp-12/2 mice is
sensitized to ligand-mediated activation. The PPARa agonist,
ciprofibrate, increased PPARa activity byw30% in hepatocytes
derived from mkp-1+/+ mice relative to untreated controls (Fig-
ure 3F). Whereas, hepatocytes derived from mkp-12/2 mice
when treated with ciprofibrate exhibited an increase in PPARa
activity that was nearly 2-fold higher than ciprofibrate-treated
mkp-1+/+ hepatocytes (Figure 3F). Importantly, treatment of he-
patocytes with the p38 MAPK inhibitor, SB203580, attenuated
ciprofibrate-induced PPARa activity in hepatocytes derived
from mkp-12/2 mice. These results suggest that MKP-1 nega-
tively regulates the sensitivity of PPARa to respond to ligand-
induced activation by dephosphorylating p38 MAPK.
Enhanced mitochondrial respiration in skeletal
muscle of mkp-12/2 mice
We next attempted to determine the mechanism through which
mkp-12/2 mice could be resistant to weight gain. Given that
mkp-12/2mice do not appear to have reduced food intake (Fig-
ure 1D), we speculated that these mice could be resistant to
weight gain due to enhanced energy consumption. We first
examined the activities of the MAPKs in skeletal muscle of
mkp-1+/+ and mkp-12/2 mice. These results demonstratedCELL METABOLISM : JULY 2006that p38 MAPK, JNK and Erk were all hyper-activated in the
skeletal muscle of mkp-12/2 mice as compared with mkp-1+/+
mice (Figure 4A, left panel) while no differences in the expression
of these MAPKs in skeletal muscle were observed (Figure 4A,
right panel). These data demonstrate that MKP-1 is also a major
MKP that inactivates the MAPKs in skeletal muscle.
In order to directly assess whether regulation of theMAPKs by
MKP-1 was linked to increased mitochondrial efficiency, and
thus enhanced energy consumption inmkp-12/2mice, wemea-
sured mitochondrial respiration in permeabilized skeletal mus-
cle fibers (Anderson and Neufer, 2006). Muscles from both red
and white vastus lateralis were dissected from mkp-1+/+ and
mkp-12/2 mice and mitochondrial respiration was measured in
the absence (V0) and presence (Vmax) of ADP. We found that
basal (V0) and maximal (Vmax) mitochondrial oxygen consump-
tion were enhanced in red (oxidative) portions of skeletal muscle
from mkp-12/2 mice as compared with mkp-1+/+ littermates
(Figure 4B). The enhanced levels of mitochondrial oxygen con-
sumption could be due simply to an increase in skeletal muscle
mitochondrial content in mkp-12/2 mice. However, using real-
time quantitative PCR for mitochondrial DNA, as a measure of
mitochondrial content, no differences were observed between
mkp-1+/+ and mkp-12/2 mice (Figure 4C). Additionally, citrate
synthase activity, another marker of mitochondrial content
was also similar in skeletal muscles of mkp-1+/+ and mkp-12/2
mice (data not shown). These findings indicate that the in-
creased levels of mitochondrial respiration in skeletal muscles
of mkp-12/2 mice is unlikely to be associated with elevated65
A R T I C L EFigure 5. Unaltered insulin-mediated glucose homeostasis and Akt activity in mkp-12/2 mice
mkp-1+/+ and mkp-12/2 mice (13–17 weeks) were subjected to hyperinsulinermic-euglycemic clamp experiments. (A) Whole-body glucose uptake, (B) glucose infusion
rates, (C) glycogen synthesis, (D) glycolysis, (E) hepatic glucose production, and (F) % insulin suppression of hepatic glucose production. Data represent mean 6 SEM
from mkp-1+/+ (n = 12) and mkp-12/2 (n = 11) mice. (G) Immunoblot analyses with anti-phospho-Akt and anti-Akt antibodies from skeletal muscle (gastrocnemius), liver
and WAT of mkp-1+/+ and mkp-12/2 mice injected i.p. with saline (0’) or 0.2 U/kg insulin for 30 or 60 min. (H) Nuclear and cytosolic fractions of liver homogenates from
15-week high-fat fed mkp-1+/+ and mkp-12/2 mice were immunoblotted with anti-phospho-JNK, Lamin b1, and HSP90 antibodies. The results shown are the mean 6
SEM of the relative change in phospho-JNK levels normalized to HSP90 and Lamin b1 levels for cytosol and nuclear fractions, respectively from mkp-1+/+ (n = 6) and
mkp-12/2 (n = 6) mice. (I) GAL4-c-Jun and 5xGAL4 luciferase were transfected into mkp-1+/+ and mkp-12/2 hepatocytes along with pRL-Renilla. Luciferase normalized
to Renilla was measured 18 hr later. Data represent the mean 6 SEM from 3 separate experiments.mitochondrial content. To determine further whether MKP-1
alters mitochondrial efficiency, we measured the expression
levels of uncoupling protein 3 (UCP-3), a mitochondrial inner
membrane protein with a putative role in uncoupling electron
transport from oxidative phosphorylation (Esteves and Brand,
2005). Consistent with the elevated respiration in skeletal
muscle, levels of UCP-3 protein were increased w1.5-fold in
mkp-12/2 mice as compared with mkp-1+/+ mice on a chow
diet (Figure 4D). Taken together, these results suggest that
MKP-1 negatively regulates mitochondrial respiration in skeletal
muscle.
Unimpaired insulin-mediated glucose homeostasis and
enhanced activation of nuclear JNK in mkp-12/2 mice
Weperformed hyperinsulinemic-euglycemic clampexperiments
to determinewhether chow fedmkp-12/2mice had altered insu-66lin sensitivity. As compared with mkp-1+/+ mice no significant
difference in insulin-stimulated whole body glucose turnover or
glucose infusion rates inmkp-12/2mice was observed (Figures
5A and 5B). Consistent with this, both whole body non-oxidative
glucose metabolism and glycolysis were unaltered inmkp-12/2
mice as compared with mkp-1+/+ mice (Figures 5C and 5D).
Basal hepatic glucose production, however, was significantly
enhanced inmkp-12/2mice (Figure 5E), but the ability of insulin
to suppress hepatic glucose production was comparable be-
tween mkp-1+/+ and mkp-12/2 mice (Figure 5F).
JNK negatively regulates insulin-mediated stimulation of Akt
by phosphorylating the insulin receptor substrate-1 (IRS-1)
resulting in the attenuation of IRS-1 tyrosyl phosphorylation
(Aguirre et al., 2000; Lee et al., 2003). Our data show that
although mkp-12/2 mice had elevated JNK activity they were
not significantly altered in their ability to regulate glucoseCELL METABOLISM : JULY 2006
MKP-1 regulates metabolism and body masshomeostasis (Figures 5A–5F). BecauseMKP-1 is localized to the
nucleus (Wu et al., 2005), its actions are presumably restricted to
the pool of activatedMAPKs that translocate there. Thus, we hy-
pothesized that insulin-mediated Akt activation is unlikely to be
affected inmkp-12/2mice. Following an intraperitoneal injection
of insulin, skeletal muscle, WAT, and liver were removed from
mkp-1+/+ and mkp-12/2 mice and examined for Akt activation.
Insulin-mediated Akt activation was not perturbed in skeletal
muscle,WAT, or liver frommkp-12/2mice (Figure 5G). These re-
sults were consistent with the observation that in the liver, insu-
lin-mediated IRS-1 tyrosyl phosphorylation was comparable be-
tween mkp-1+/+ and mkp-12/2 mice (Figure S3). Next, we
performed cellular fractionation experiments to determinewhich
pool of JNK was hyper-activated inmkp-12/2mice. To enhance
JNK activity we usedmice that were fed aHFD for 15weeks (Hir-
osumi et al., 2002). Following cytosolic and nuclear fraction-
ation, we found that there was an increase in the amount of
phosphorylated JNK in the nucleus, with a concomitant but
slight decrease of phosphorylated JNK in the cytosol, from livers
ofmkp-12/2mice as compared withmkp-1+/+ mice (Figure 5H).
As a surrogate read-out for JNK activity in the nucleus, a c-Jun-
GAL4 chimera was transfected intomkp-1+/+ andmkp-12/2 he-
patocytes along with GAL4-luciferase to measure JNK-medi-
ated phosphorylation and activation of the transcription factor,
c-Jun. Consistent with the fractionation experiments, JNK-
mediated activation of c-Jun was increased by w3 fold in
mkp-12/2 hepatocytes (Figure 5I). These data demonstrate that
mkp-12/2mice exhibit enhanced JNK activity in the nucleus, but
not the cytosol. Hence, MKP-1 dephosphorylates the nuclear
pool of JNK, suggesting that the action of MKP-1 on JNK in
the nucleus is spatially distinct from the regulation of JNK activ-
ity in the cytosol.
mkp-12/2 mice are resistant to diet-induced
obesity but not glucose intolerance
Our data demonstrates that mkp-12/2 mice are resistant to
weight gain on a chow diet (Figure 1) but show nomarked differ-
ences in insulin sensitivity (Figure 5). Therefore, we tested
whether mkp-12/2 mice were resistant to diet-induced obesity
and the development of glucose intolerance which ensues
upon feeding a HFD. When fed a HFD (w55% fat content), we
observed that mkp-12/2 mice were significantly (p < 0.001)
resistant to weight gain, primarily due to reduced total body ad-
iposity (Figure S4A) following 12 weeks of feeding (Figures 6A
and 6B).mkp-12/2mice also continued to be resistant to the ac-
quisition of a fatty liver on a HFD (Figures S4B and S4C). Female
mkp-12/2 mice were also significantly resistant to weight gain
on a HFD (Figure S4D). Fasting glucose levels on either
a chow diet or following 4 weeks on a HFD were not significantly
different between mkp-1+/+ and mkp-12/2 mice (Figure 6C).
Fasting insulin levels were also similar in mkp-12/2 mice as
compared with mkp-1+/+ mice after a 4 week HFD (Figure 6D),
suggesting that mkp-12/2 mice are equally susceptible to the
development of hyperinsulinemia on a HFD. Analyses of
serum chemistries for mice on a chow diet revealed that
mkp-12/2 mice had significantly (p < 0.05) reduced free fatty
acid and serum triglyceride levels (Table S1). No significant
differences were observed between mkp-1+/+ and mkp-12/2
mice when cholesterol, high density lipoprotein and b-hydroxy-
butyrate were measured (Table S1). However, cholesterol levels
of mkp-12/2 mice were significantly (p < 0.05) lower as com-CELL METABOLISM : JULY 2006pared withmkp-1+/+ mice following a HFD (Table S1). No signif-
icant differences in either leptin or adiponectin levels were
observed between mkp-1+/+ and mkp-12/2 mice under chow
or after 12 weeks of HFD feeding (Table S1). These results
demonstrate that mkp-12/2 mice are resistant to diet-induced
obesity.
Mkp-12/2 mice showed unimpaired effects of insulin on
glucose homeostasis on a chow diet potentially due to the re-
striction of the activated pool of JNK to the nucleus (Figure 5).
Therefore, we hypothesized that mkp-12/2 mice when placed
on aHFD should be lean and protected fromdeveloping glucose
intolerance. To test this, we compared glucose tolerance tests
(GTT) from mkp-1+/+ and mkp-12/2 mice on a chow diet with
those following 4 weeks on a HFD. mkp-12/2 mice on a chow
diet cleared glucose from the periphery at a slightly lower level
of efficiency as compared with mkp-1+/+ mice although this dif-
ference was not statistically significant (Figure 6E). Following 4
weeks on a HFD, both mkp-1+/+and mkp-12/2 mice became
significantly (p < 0.0001) glucose intolerant (Figure 6E).We found
that even after 12 weeks on a HFD when mkp-12/2 mice were
significantly leaner (p < 0.001) as compared with mkp-1+/+
mice (Figures 6A and 6B), GTT analyses showed that mkp-1+/+
and mkp-12/2 mice became dramatically glucose intolerant to
comparable levels (Figure 6E). Collectively, these data provide
strong evidence for the uncoupling of diet-induced obesity and
glucose intolerance in mice lacking MKP-1 expression.
Enhanced energy expenditure and respiration
rate in high fat fed mkp-12/2 mice
To further investigate the cause of the resistance to diet-induced
obesity in mkp-12/2 mice we determined the respiratory rate
(VO2), energy expenditure, respiratory quotient (RQ), and loco-
motor activity after 15 weeks on a HFD. Energy expenditure
and respiratory rate (normalized to body weight) were both sig-
nificantly higher in mkp-12/2 mice as compared with mkp-1+/+
mice (p < 0.05) (Figures 7A and 7B). The utilization of carbo-
hydrate to fat in mkp-12/2 mice was equivalent to that of
mkp-1+/+ mice as indicated by their identical RQ levels
(Figure 7C). Obese mkp-1+/+ mice on a HFD were less active
than when on a chow diet (Figure 7D and 1E). In contrast,
mkp-12/2 mice maintained their level of locomotor activity on
a HFD as compared to when fed a chow diet (Figure 7D and
1E). These data indicate that mkp-12/2 mice are not hyper-
active per se, nevertheless their maintained level of locomotor
activity on a HFD relative to mkp-1+/+ mice could contribute to
their resistance to diet-induced obesity. Reduced levels of total
body adiposity inmkp-12/2mice (Figure S4A) could additionally
occur as a result of decreased levels of food consumption. How-
ever, when food intake was measured in these HFD fed mice,
mkp-12/2 mice actually consumed more food as compared
to mkp-1+/+ mice (mkp-1+/+; 7.2 6 1.5 Kcal/Kg/h [n = 7] versus
mkp-12/2; 11.66 3.8 Kcal/Kg/h [n = 6]). Therefore, even though
mkp-12/2 mice consume more food than mkp-1+/+ mice on
a HFD diet, they remain leaner. These results support the inter-
pretation thatmkp-12/2mice are resistant to diet-induced obe-
sity due, in part, to increased levels of energy expenditure.
Discussion
In this report, we show that mkp-12/2 mice exhibit enhanced
p38 MAPK, JNK and Erk activities in insulin-responsive tissues.67
A R T I C L EFigure 6. Resistance to HFD-induced obesity but
not glucose intolerance in mkp-12/2 mice
mkp-1+/+ and mkp-12/2 mice (5–6 weeks old) were
placed on a HFD for 4–12 weeks.
A) Representative image of male mkp-1+/+ and
mkp-12/2 mice following a 12-week HFD.
B) Body weight of male mkp-1+/+ (n = 7) and
mkp-12/2 (n = 11) mice monitored weekly for
12 weeks (*; p < 0.05 and **; p < 0.01).
C) Fasting glucose levels from mkp-1+/+ and
mkp-12/2 mice on a chow diet or a 4 week HFD
(n = 9–14).
D) Fasting insulin levels were determined from
mkp-1+/+ and mkp-12/2 mice on a chow diet or
a 4 week HFD (n = 12–13).
E) Fasted 10–14 week old mice maintained on
a chow diet (mkp-1+/+ [n = 7–8] and mkp-12/2 [n =
8]) or fasted mice that have been on a HFD for
4 weeks (mkp-1+/+ [n = 9] and mkp-12/2 [n = 9]) or
12 weeks (mkp-1+/+ [n = 5] and mkp-12/2 [n = 4])
were subjected to GTTs. Data represent the
mean 6 SEM. By One-way ANOVA p < 0.001;
mkp-1+/+chowversusmkp-1+/+HFD4and12weeks;
mkp-12/2 chow versus mkp-12/2 HFD 4 and 12
weeks. p > 0.1; mkp-1+/+ versus mkp-12/2 on
chow, HFD 4 and 12 weeks.Consistent with their lean phenotype,mkp-12/2mice were pro-
tected from diet-induced obesity. Remarkably, although lean
and resistant to diet-induced obesity, mkp-12/2 mice were not
insulin sensitive and were susceptible to the development of
glucose intolerance and hyperinsulinemia when fed a HFD.
These observations were surprising in context of the role for
JNK in promoting obesity and insulin resistance. We resolved
this dichotomy by demonstrating that in the absence of MKP-
1, JNK activation is enhanced in the nucleus, and not cytosol.
Hence, the dephosphorylation of the MAPKs by MKP-1 in the
nucleus is spatially and functionally distinct from the regulation
of the MAPKs in the cytosol (Figure 7E).
In WAT, liver and skeletal muscle ofmkp-12/2mice we found
that p38 MAPK and JNK were hyper-activated. Erk was hyper-68activated in WAT and skeletal muscle, but not in the liver of
mkp-12/2 mice. These results demonstrate that MKP-1 is a
major physiological regulator of p38MAPK, JNK and Erk activity
in insulin-responsive tissues and that hyper-activation of one or
more of theseMAPKs are causal to themetabolic phenotype ob-
served inmkp-12/2mice. Thesemkp-12/2mice havebeen stud-
ied previously but nometabolic defects were reported. One pos-
sibility for this is that there could have been differences in the
composition of the chow diet used in the previous study (Dorf-
man et al., 1996). Genetic background is not likely to be a factor
given that themice used in this study were derived from the orig-
inal strain (Dorfman et al., 1996). However, we cannot rule-out
the possibility that themixed genetic background towhich these
mice were bred could be a contributing factor to the phenotype.CELL METABOLISM : JULY 2006
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been demonstrated previously. Hyper-activation of JNK is impli-
cated in insulin resistance (Hirosumi et al., 2002), whereas p38
MAPK has been shown to be involved in the positive regulation
of energy expenditure (Puigserver et al., 2001). Erk-1-deficient
mice were shown to be resistant to diet-induced obesity and
were protected from the development of insulin resistance
(Bost et al., 2005). It is clear that each of these individual MAPKs
can affect metabolic regulation. However, in the absence of
MKP-1, both p38 MAPK and JNK, and in some cases, Erk are
all hyper-activated in the same tissue. Thus, the phenotype
observed in mkp-12/2 mice is not a simple recapitulation of
hyper-activation of each of these individual MAPKs but rather,
Figure 7. Enhanced energy expenditure and oxygen consumption in mkp-12/2
mice
mkp-1+/+ andmkp-12/2mice fed a HFD for 15 weeks were subjected to open cir-
cuit calorimetry. (A) Energy expenditure, (B) oxygen consumption, (C) respiratory
quotient (RQ), and (D) activity were measured. Graphs represent the mean6 SEM
formkp-1+/+ (n = 7) andmkp-12/2 (n = 6) mice (*;p < 0.05). (E) Model depicting the
nuclear inactivation of the MAPKs by MKP-1 in the control of gene expression
events involved in fatty acid metabolism and energy expenditure. In the cytosol
the MAPKs are regulated independently of MKP-1.CELL METABOLISM : JULY 2006represents a unique phenotype depicting the combined actions
of hyper-activation of either one, two or all three of the MAPKs.
The complexity of the interplay amongst the MAPKs is further
highlighted by evidence indicating that the MAPKs exhibit
cross-talk. For example, it has been shown that both p38
MAPK and JNK can negatively regulate Erk activity (Shen
et al., 2003; Zhang et al., 2001). In this regard, cross-talk
between the MAPKs might explain the paradoxical decrease
in Erk activity in the liver when both p38 MAPK and JNK were
hyper-activated in mkp-12/2 mice. The results presented here
emphasize the physiological specificity within the family of
MKPs. Most noteworthy, are the differences, and some similar-
ities, between our results and mice deficient in other MKPs. For
example, MKP-4 knock-out mice are embryonic lethal (Christie
et al., 2005). In contrast, we and others have shown recently that
MKP-1 is involved in the regulation of innate immunity (Chi et al.,
2006; Hammer et al., 2006; Salojin et al., 2006; Zhao et al., 2006)
similar to that of MKP-5 (Zhang et al., 2004). Taken together with
our results these studies clearly establish that the MKPs engage
in non-redundant physiological functions.
We found that mice lackingMKP-1 have reduced adiposity at-
tributed, at least in part, to smaller adipocyte size. This suggests
thatMKP-1 regulates pathways that control lipid homeostasis. It
is conceivable that hyper-activation of Erk and/or JNK in adipo-
cytes of mice lacking MKP-1 impairs PPARg-mediated lipogen-
esis. Alternatively,mkp-12/2mice might have reduced fat mass
because of fewer adipocytes. MKP-1 has been implicated in the
positive regulation of adipogenesis in pre-adipocytes (Sakaue
et al., 2004). Contrary to those data, however, we found unal-
tered adipogenesis in primary MEFs isolated from mkp-12/2
mice. What is interesting is the observation that despite the sig-
nificant disparity in fat mass, mkp-12/2 mice displayed equiva-
lent levels of leptin to mkp-1+/+ mice. We speculate that en-
hanced MAPK activity in mkp-12/2 mice might increase leptin
expression in context of a lean phenotype to levels comparable
to that observed inmkp-1+/+mice. Indeed, leptin expression has
been shown to be dependent upon Erk activity in certain cell
types (Bradley et al., 2002). In addition, we have shown that
mkp-12/2 mice have elevated levels of a number of cytokines,
in particular TNFa (Chi et al., 2006), which can induce the ex-
pression of leptin in fat (Sarraf et al., 1997). Transgenic mice
overexpressing UCP-3 in skeletal muscle also exhibit dramati-
cally reduced levels of adipose tissue but their levels of leptin
are equivalent to that of wild-type mice (Clapham et al., 2000).
In line with this, we too observe increased levels of UCP-3 ex-
pression in skeletal muscle of mkp-12/2 mice.
MKP-1 may indirectly link the regulation of body adiposity
through its effect on skeletal muscle metabolism since we dem-
onstrate that it negatively regulates mitochondrial respiration in
skeletal muscle. PGC-1a which stimulates the transcription of
a number of mitochondrial genes involved in energy expendi-
ture, is a direct target for activation by p38 MAPK (Puigserver
et al., 2001). Therefore, the enhanced levels of p38 MAPK activ-
ity observed in skeletal muscle may cause increased PGC-1a-
mediated expression of genes involved in energy consumption,
thereby providing at least one of the contributing factors that
promotes the lean phenotype ofmkp-12/2mice. At this juncture
we cannot exclude contributions from other sites of MKP-1 ac-
tion that may also regulate energy expenditure. In particular,
MKP-1 is expressed in the hypothalamus (Mastaitis et al.,
2005), and it may influence MAPK-dependent signaling events69
A R T I C L Emediated by either insulin and/or leptin at this site. Although it
has been suggested that insulin-mediated activation of Erk in
the hypothalamus controls sympathetic outflow to skeletal mus-
cle (Rahmouni et al., 2004) which indirectly stimulates energy
expenditure, it is not firmly established whether the metabolic
effects of leptin in the hypothalamus are dependent upon the ac-
tivity of the MAPKs. On the contrary, evidence seems to imply
that hyper-activation of Erk alone promotes obesity (Bost
et al., 2005; Rodriguez et al., 2006). In context of our findings,
such results serve to further highlight the complexity of the com-
binatorial effects of JNK, p38 MAPK and Erk in the control of
metabolic homeostasis.
Our results have uncovered an important regulatory role for
MKP-1 in hepatic lipid metabolism. Mice lacking MKP-1 were
resistant to the acquisition of a fatty liver suggesting that
MKP-1 negatively regulates hepatic fatty acid oxidation. Indeed,
we observed increased expression levels of the liver isoform of
carnitine palmitoyltransferase I in fasted mice lacking MKP-1
expression. Hepatic fatty acid oxidation also proceeds through
activation of the PPAR pathway. In this regard, MKP-1 was
found to control the sensitivity of PPARa to be activated by
ciprofibrate, a PPARa-specific ligand, in a p38MAPK-dependent
manner. It appears reasonable to propose that in the liver, reg-
ulation of p38 MAPK byMKP-1 may set the sensitivity of PPARa
to become activated by its physiological ligands. In the liver, p38
MAPK has also been implicated in the positive regulation of glu-
coneogenesis (Cao et al., 2005). We observed that basal hepatic
glucose production is increased in mkp-12/2 mice correlating
with the elevated levels of p38 MAPK. Hepatic insulin action ap-
pears intact in the liver under the dose of insulin employed in
these clamp studies, as well as in response to the acute actions
of insulin on IRS-1 tyrosyl phosphorylation, and Akt activation
which were unaffected in the livers of mkp-12/2 mice. Hence,
we favor the interpretation that the enhanced levels of basal
hepatic glucose production is likely due to increased levels of
gluconeogenesis rather than being reflective of hepatic insulin
resistance.
Typically, leanness correlates with increased insulin sensitiv-
ity. Therefore, the most provocative finding of this study is the
observation that mice lacking MKP-1 are neither insulin sensi-
tive, even though they are lean, nor protected from the loss of
glucose homeostasis as a result of high-fat feeding, but yet
are resistant to diet-induced obesity. A similar uncoupling of glu-
cose intolerance following a HFD in context of a lean phenotype
has been observed in transgenic mice overexpressing PPARa in
skeletal muscle (MCK-PPARa) (Finck et al., 2005). MCK-PPARa
mice were suggested to develop glucose intolerance as a con-
sequence of enhanced fatty acid oxidation and importantly, this
occurred without any apparent alteration to insulin signaling
(Finck et al., 2005). It is possible that the enhanced level of
p38 MAPK activity in skeletal muscles of mkp-12/2 mice might
increase PPARa-mediated fatty acid oxidation, similar to that
in the liver, to precipitate an analogous pathophysiological path-
way for the development of glucose intolerance following a HFD
independently of the effects on insulin signaling.
Despite JNK being elevated in all insulin-responsive tissues in
chow fed mkp-12/2 mice we found that insulin-mediated glu-
cose regulation as measured by hyperinsulinemic-euglycemic
clamp experiments revealed equivalent levels of whole body
glucose turnover in mkp-12/2 mice as compared to controls.
We reasoned that the lack of effect of MKP-1 on whole body in-70sulin-mediated glucose uptake could be due to the fact that
MKP-1 is localized to the nucleus (Wu et al., 2005), and thus
only regulates that pool of active MAPKs, which either may
not interfere with or have access to, cytosolic components of
the insulin signaling pathway that control glucose uptake
(Figure 7E). Three lines of evidence support this notion. First,
neither IRS-1 tyrosyl phosphorylation, which is attenuated by
JNK, nor Akt activation in response to insulin, was appreciably
altered in mkp-12/2 mice. Second, we found that the pool of
hyper-activated JNK accumulated in the nucleus of livers
derived from mkp-12/2 mice. Third, JNK-mediated c-Jun
activation was enhanced in the nucleus of mkp-12/2 hepato-
cytes. Together, these results imply that MKP-1 specifically de-
phosphorylates the nuclear pool of MAPKs, as anticipated, but
here we provide direct evidence for this spatially restricted
sub-cellular regulation. The consequences of MKP-1 deficiency
results in the functional uncoupling of the targets of JNK in the
cytosol from those that reside in the nucleus. Although it has
been inferred that the discrete sub-cellular localization of the
MKPs is important for their physiological function (Volmat
et al., 2001), the data described herein provides genetic evi-
dence that this is indeed the case. Increased activity of JNK,
and potentially p38MAPK and Erk in the nucleus might enhance
transcriptional activation of genes that are involved in the
regulation of fatty acid metabolism and energy expenditure
(Figure 7E).
In summary, we demonstrate that MKP-1 plays a major
physiological role as a dual-specificity phosphatase for the inac-
tivation of the MAPKs in insulin-responsive tissues. Further, we
provide insight into the consequences of the combinatorial ac-
tions of enhancedMAPK activity in the progression of metabolic
syndrome. By defining MKP-1 as a molecular target that uncou-
ples diet-induced obesity from glucose intolerance raises the
possibility that pharmacological inactivation of MKP-1 can be
used as a therapy for the specific treatment of obesity.
Experimental procedures
Maintenance of mice
Mice containing a disruption within exon 2 ofMKP-1 (mkp-12/2) were derived
by implantation of heterozygotic (mkp-1+/2) 129J/C57BL6 embryos obtained
from Bristol-Myers Squibb (Princeton, NJ) (Dorfman et al., 1996) into surro-
gate mothers. All experiments were performed with mice generated from in-
ter-crossed heterozygous breeders. mkp-1+/+ and mkp-12/2 mice were
maintained on a rodent chow #2018 (Harlan Teklad, IN). For HFD studies,
5-6 week oldmale and female mice were placed on TD 93075 (Harlan Teklad)
diet for 12-15 weeks. For genotyping, PCR analysis was employed using
triple primers consisting of forward primers 50-CCAGGTACTGTGTCGGT
GGTGC-30 and 50-CAGCGCATCGCCTTCTATCGCC-30, with reverse primer
50-GCTTTCTATATCCTCCTGG-30.
Isolation of primary cell cultures and adipogenesis assays
Primary mouse embryonic fibroblasts (MEF) were derived as described pre-
viously (Wu and Bennett, 2005). For adipogenesis assays, primary MEFs
(passage 3-4) were cultured in growth media (Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum
(FBS; Sigma, St. Louis, MO), 10 U/ml penicillin (Sigma) and 50 mg/ml strepto-
mycin (Sigma). Two days post confluence, cells were switched to adipogen-
esis media (DMEM supplemented with 10%FBS, 10 U/ml penicillin, 50 mg/ml
streptomycin, 10 mg/ml insulin [Sigma], 5 mM dexamethasone [Sigma], and
0.5 mM 3-Isobutyl-1-methylxanthine [IBMX; Sigma]). Adipogenesis media
was changed every 48 hr for 14 days. Cells were washed with phosphate-
buffer saline (PBS), fixed in 10% formalin at room temperature for 15 min,
and stained with 0.5% Oil-red-O in isopropyl alcohol:distilled water [60:40]CELL METABOLISM : JULY 2006
MKP-1 regulates metabolism and body massfor 30 min at 37ºC. The absorbance of the extracted stain was measured at
510 nm. Primary hepatocytes were isolated using a modified collagenase di-
gestion method as described previously (Boyer et al., 1990). Hepatocytes
were cultured in DMEM supplemented with 10% FBS, 50 nM insulin, 1 mM
dexamethasone, 1 mM sodium pyruvate, 10 U/ml penicillin and 50 mg/ml
streptomycin.
Histological analysis of tissue
WAT was isolated from mkp-1+/+ and mkp-12/2 mice and fixed in 4% para-
formaldehyde in PBS and processed for paraffin sections and stained by
hematoxylin and eosin. Cross-sectional areas of adipocytes were measured
using Image J software by counting at least 300 individual cells from random
fields in histological sections. Non-perfused livers were digested in chloro-
form-methanol to determine hepatic triglyceride levels. Lipid layers were
separated using H2SO4 and the triglyceride concentration was determined
with a triglyceride assay kit (Sigma Diagnostics) according to the manufac-
turer’s instructions. Livers were fixed either in 4% paraformaldehyde-PBS
and stained by hematoxylin and eosin, or snapped-frozen in 5-methylbutane
(Sigma). Cryostat sections of livers were fixed with 4% paraformaldehyde-
PBS for 1 hr and cyroprotected with 20% sucrose prior to staining with 4%
Oil Red O for 2 hr. Liver tissues were fixed with 10% formalin in PBS for
2 hr then stained with 4% Oil Red O solution for 2 hr.
Biochemical analysis of tissue
For immune complex kinase assays, liver and gastrocnemius muscle were
homogenized with 10 or 20 volumes of homogenizing buffer (25 mM Tris.
HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 10%
glycerol, 1mMDTT, 0.5% sodiumdeoxycholic acid) supplementedwith pro-
tease and phosphatase inhibitors (5 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mg/
ml pepstatin A, 1 mM PMSF, 1 mM benzamidine, 1 mM Na3VO3, and 10 mM
NaF). WAT was lysed in RIPA buffer (25 mM Tris. HCl pH 7.4, 150 mM NaCl,
5 mM EDTA, 1% NP-40, 0.1 % SDS, 1.0 % sodium deoxycholic acid). Ho-
mogenates were lysed for 30 min prior to clarification at 20,800 g for
30 min at 4ºC. Protein concentrations were determined by Coomassie
Protein Reagent (Pierce, Rockford, IL). Erk2, JNK, or p38 MAPK were immu-
noprecipitated with anti-Erk2 (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-JNK1 (Santa Cruz Biotechnology) or anti-p38 MAPK (Santa Cruz Bio-
technology) antibodies, respectively for 4 hr or overnight at 4ºC. Erk2 and
JNK1 immune complexes were collected on Protein A Sepharose and
Protein G Sepharose was used to capture p38 MAPK immune complexes.
Purified GST-c-Jun (amino acids 5-89 of c-Jun) protein was used to precip-
itate JNK. The complexes were washed with lysis buffer and kinase buffer.
The kinase reactions were performed with 50 ml of kinase buffer for 30 min
at 30ºC, using 1 mg of myelin basic protein (Sigma) as a substrate for Erk2
or p38 MAPK or 1 mg GST-c-Jun as a substrate for JNK. Reactions were ter-
minated by the addition of sample buffer and substrates were resolved by
SDS-PAGE and visualized by autoradiography. Tissue homogenates were
resolved by SDS-PAGE and proteins were transferred to Immobilon-P mem-
branes and immunoblotted with antibodies to Erk1/2, JNK, p38 MAPK, the
liver isoform of carnitine palmitoyltransferase I (CPT-1L) (Alpha Diagnostic In-
ternational) or UCP-3 (Calbiochem-Novabiochem). To assess insulin-medi-
ated Akt activation in vivo, 10-14 week old males were fasted overnight
and injected intraperitonealy with saline or 0.2 U/kg insulin (Novo Nordisk,
Novolin) for 30 or 60 min. WAT, gastrocnemius, and liver were isolated and
snap-frozen in liquid nitrogen. Tissue homogenates were prepared and pro-
tein was separated on SDS-PAGE and immunoblotted with anti-phospho-
Akt and anti-Akt antibodies (Cell Signaling Technology). To assess insulin-
mediated IRS-1 tyrosyl phosphorylation, IRS-1 was immunoprecipiated
from liver homogenates with IRS-1 antibodies (Santa Cruz Biotechnology),
immune complexes were immunoblotted with either anti-IRS-1 or anti-phos-
photyrosine (clone 4G10) antibodies.
Sub-cellular Fractionation
Liver fractionation was performed as previously described (Tata et al., 1974)
with the following modifications. Sucrose buffers contained 5 mg/ml leupep-
tin, 5 mg/ml aprotinin, 1 mg/ml pepstatin A, 1mMbenzamidine, 2mMNa3VO3,
and 50 mM NaF. The nuclear pellet was resuspended in RIPA buffer (1.0%
NP-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 0.1% SDS,
1% sodium deoxycholate), along with protease and phosphatase inhibitors.
Liver fractions were immunoblotted with phospho-JNK (Cell Signaling Tech-CELL METABOLISM : JULY 2006nology), Lamin b1 (Santa Cruz Biotechnology) or HSP-90 (BioVision Inc) an-
tibodies. The amount of phosphorylated JNK was normalized to either HSP-
90 or lamin b1 for cytosolic or nuclear fractions, respectively.
Glucose tolerance test and blood chemistry
Overnight fasted 10-14 week old male mice or male mice that have been on
a HFD for 4-5 weeks were intraperitonealy injected with D-glucose (20% so-
lution; 1 g/kg body weight). Tail vein blood was collected at 0, 30, 60 and
120 min following glucose injection and blood glucose level was measured
with a BeckmanGlucose Analyzer 2 (Beckman, Fullerton, CA). Plasma insulin
levels were measured by radioimmunoassay using kits from Linco Research
(St. Charles, MO). Plasma was collected from overnight fasted mice and the
Yale Mouse Metabolic Phenotyping Center was used to determine the
plasma concentration of cholesterol, high density lipoprotein, triglyceride,
free fatty acid, and b-hydroxybutyrate. Leptin and adiponectin measure-
ments were performed by Linco Research Inc. (St. Charles, Missouri) from
mice that were fed either a chow or HFD for 12 weeks. Samples were ob-
tained from mice that were fasted overnight following 1.5 hr re-feeding.
Body composition, hyperinsulinemic-euglycemic
clamps and metabolic calorimetry
Whole body fat and lean mass were measured from unanesthetized male
mice using 1H-magnetic resonance spectroscopy (Bruker Mini-spec Ana-
lyzer; Echo Medical Systems, Houtson, TX). At least 4 days before clamp
experiments, whole body fat and lean mass were measured in awake age-
matched mice using 1H-MRS. Following the body composition analysis,
mice were anesthetized, and surgery was performed to establish an indwell-
ing catheter in the right internal jugular vein (Park et al., 2005). Following an
overnight fast, a 2 hr hyperinsulinemic-euglycemic clamp was conducted
in awakemice with a continuous infusion of insulin (15 pmol/kg/min; Humulin,
Eli Lilly, Indianapolis, IN) and variable infusion of 20% glucose (Park et al.,
2005). Basal and insulin-stimulated whole body glucose turnover was esti-
mated with a continuous infusion of [3-3H]glucose (Perkin Elmer Life and
Analytical Sciences, Boston, MA) for 2 hr prior to and throughout the clamps
(Park et al., 2005). Metabolic measurements for activity, food, and energy ex-
penditure were performed using the Comprehensive Lab Animal Monitoring
System (CLAMS: Columbus Instruments, Columbus, OH, USA). During data
analysis, energy expenditure and feeding were normalized to body weight.
Respiratory quotient (RQ) and energy expenditure were calculated from the
gas exchange data. Activity was measured using infrared beams to count
the amount of beam breaks during the specified measurement period. Feed-
ing was measured by recording the difference in the scale measurement of
the Center-Feeder from one time point to another.
Skeletal muscle mitochondrial respiration
and mitochondrial content assays
Mitochondrial oxygen consumption was determined in permeabilized fiber
bundles from red and white portions of the vastus lateralis muscle as previ-
ously described (Anderson and Neufer, 2006). Briefly, basal (Vo, no ADP) and
maximal (Vmax, 330 mMADP) respiration supported by pyruvate (500 mM) and
malate (200 mM) were measured at 25ºC using a modified Clark-type O2-
electrode (Hansatech Instruments). Respiration rates are expressed as
nmol O2 consumed min
-1 mg dry weight-1. For assessment of mitochondrial
content red and white vastus lateralis muscles were isolated from mkp-1+/+
and mkp-12/2 mice. DNA was isolated with the DNEasy DNA isolation kit
(Qiagen) and PCR was performed with the BioRad iQ5 Real-Time PCR De-
tection System using Sybr Green fluorophore with the following primers
for: 18S – 50-TAGAGGGACAAGTGGCGTTC-30 and 50-CGCTGAGCCAGTC
AGTGT-30, mouse mitochondrial Cox1 50-GCCCCAGATATAGCATTCCC-30
and 50- GTTCATCCTGTTCCTGCTCC-30. Critical thresholds of mitochondrial
DNA were subtracted from the critical thresholds of nuclear DNA to obtain
a ratio of mitochondrial DNA/nuclear DNA.
Luciferase reporter assays
Luciferase and Renilla activities were measured using the dual luciferase
reporter assay system kit from Promega (Madison,WI) according to theman-
ufacturer’s instructions. Primary mkp-1+/+ and mkp-12/2 hepatocytes were
transiently transfected with 1.0 mg (ACO)3-TK-Luc and 50 ng pRL-Renilla or
0.5 mg GAL4-c-Jun, 0.5 mg 5 x GAL4-Luciferase and 50 ng pRL-Renilla
with lipofectamine 2000. Hepatocytes were stimulated for 5 hr with 200 mM71
A R T I C L Eciprofibrate or 200 mM ciprofibrate plus 5 mM SB203580 prior to measuring
luciferase and renilla activities.
Statistical analyses
MAPK assayswere quantitated using LabWorks 4.0 densitometric software
(UVP Inc., Upland, CA). Statistical significances between groups were calcu-
lated by two-way t test assuming equal variances using Microsoft Excel Sta-
tistical Analysis Tool (Microsoft, Redmond, WA). Growth curves and GTTs
were analyzed byOne-way ANOVAwith Bonferoni post-test performed using
GraphPad InStat version 3.05 for Windows 95/NT (GraphPad Software, San
Diego).
Supplemental data
Supplemental data include one table and four figures and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/4/1/61/
DC1/.
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